American Academy of Ophthalmic Professionals members will enjoy expanded opportunities for career advancement and access to the most up-to-date information in the field, including a new technician learning track at the Academy’s annual meeting in San Francisco this November.
According to the company, the financing will advance novel treatments for glaucoma and other chronic ophthalmic diseases by supporting multiple US clinical trials of its drug delivery platform.
Severe ocular surface and corneal damage an unseen public health burden.
The second issue of the 2023 Video Journal of Cataract, Refractive, & Glaucoma Surgery offers a compilation of 27 surgical highlights from the ESCRS meeting in Milan, providing valuable education for global anterior segment surgeons.
In the sport, which is a hybrid of badminton, ping-pong and tennis, players use a plastic-perforated ball, slightly heavier than a whiffle ball, and wooden or composite paddles that are about twice the size of ping-pong paddles, with a high potential for eye injuries.
Take a look at a review of the highlights and hottest stories from Ophthalmology Times during the week of July 2, 2023.
The company announced its contract manufacture, NextPharma, completed filling of the drug materials into strips of 10 single-use vials for use in upcoming glaucoma trial.
In the sport, which is a hybrid of badminton, ping-pong and tennis, players use a plastic-perforated ball, slightly heavier than a whiffle ball, and wooden or composite paddles that are about twice the size of ping-pong paddles, with a high potential for eye injuries.
The Icahn School of Medicine at Mount Sinai opened the Center for Ophthalmic Artificial Intelligence and Human Health, which is dedicated to advancing artificial intelligence to offer faster diagnosis and treatment.
The India-based pharmaceutical company is taking its first steps into ophthalmology with the announcement.
Bausch + Lomb has agreed to acquire the Blink product line for $106.5 million.
A new study found an approach that identifies high-risk patients so all preemies don’t need to undergo an invasive eye exam.
Since 2014 when a sheet of retinal pigment epithelial cells derived from iPS cells was transplanted into patients with age-related macular degeneration, clinical trials have been conducted with various cell types derived from iPS cells.
In a study of 1.7 million older Americans by a team of researchers from the University of Toronto, those living in counties with an average temperature of 60°F or above had an increased chance of suffering serious vision impairment than those in cooler counties.
A study found the approach identifies high-risk patients so all preemies don’t need to undergo an invasive eye exam.
Surgeon discusses latest trends for treating cornea.
Trainees learn to recognize key pathologies seen in fundus examinations, OCT images
OCT methods are invaluable in the assessment of patients with the condition.
Clinical trial investigator Victor H. Gonzalez, MD, presented data at the 83rd Scientific Sessions of the American Diabetes Association in San Diego, California.
Orbis International physician spotlights the latest trends for cataract surgery training.
Procedures in the pipeline hold greater appeal for cataract and refractive surgeons, patients.
Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss IAT for CRAO within 16 hours.
Special Superior Court Judge Mark A. Davis ruled that Michael Woodcock, MD’s failure to answer court filings did not mean he admitted his guilt in the allegations made by Cumberland County Hospital System.
According to Horizon Therapeutics, the analysis shows subclinical spinal cord lesions were associated with future NMOSD attacks. The analysis was being presented at the 9th Congress of the European Academy of Neurology in Budapest.
Results reported in JAMA Ophthalmology show that about 20% of those with diabetic retinopathy have a case that could threaten their vision.
The investigators evaluated corrective surgery procedures to determine their effect on ocular outcomes.
According to the companies, the divested assets will include Xiidra and SAF312, a potential therapy for chronic ocular surface pain. The deal is expected to close later this year.
In his role as president elect, SriniVas Sadda, MD, will continue to serve on the board as well as begin planning for his term as president, which will kick off next May at the conclusion of ARVO’s 2024 Annual Meeting in Seattle, Washington.
As part of its effort, the company is kicking off a new social media campaign in July designed to increase the understanding of dry eye disease.
